Article
Biochemistry & Molecular Biology
Marcia Bellon, Izabela Bialuk, Veronica Galli, Xue-Tao Bai, Lourdes Farre, Achilea Bittencourt, Ambroise Marcais, Michael N. Petrus, Lee Ratner, Thomas A. Waldmann, Vahid Asnafi, Antoine Gessain, Masao Matsuoka, Genoveffa Franchini, Olivier Hermine, Toshiki Watanabe, Christophe Nicot
Summary: The epigenetic alteration of FHIT was found to be specifically present in chronic and acute ATL patients, while absent in asymptomatic HTLV-I carriers and TSP/HAM patients. The extent of FHIT methylation in ATL patients was quantitatively comparable in virus-infected and non-infected cells. Results suggest that germinal epigenetic mutation of FHIT may predispose individuals to the development of ATL diseases.
Review
Medicine, General & Internal
Michi Miura, Tadasuke Naito, Mineki Saito
Summary: Human T-cell leukemia virus type 1 (HTLV-1) is a replication-competent human retrovirus that is associated with two types of diseases, adult T-cell leukemia-lymphoma (ATL) and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Although most infected individuals remain asymptomatic, a subpopulation develops these diseases. The complex virus-host interactions and the host immune response may regulate the development of HTLV-1-associated diseases.
FRONTIERS IN MEDICINE
(2022)
Article
Clinical Neurology
Tomoo Sato, Junji Yamauchi, Naoko Yagishita, Natsumi Araya, Naoki Takao, Yuki Ohta, Eisuke Inoue, Masaki Takahashi, Makoto Yamagishi, Yutaka Suzuki, Kaoru Uchimaru, Naoki Matsumoto, Yasuhiro Hasegawa, Yoshihisa Yamano
Summary: This study evaluated the long-term safety and efficacy of the anti-CCR4 antibody mogamulizumab in patients with HAM/TSP. The results showed that mogamulizumab had long-term safety and inhibitory effects on the progression of lower limb motor disability in HAM/TSP patients.
Review
Immunology
Antoine Gessain, Jill-Lea Ramassamy, Philippe V. Afonso, Olivier Cassar
Summary: The African continent has a high prevalence of the oncogenic retrovirus HTLV-1, with an estimated two to five million infected individuals. However, there is limited data on the epidemiological aspects, such as prevalence, risk factors, and geographical distribution. This is due to a lack of large-scale and representative studies, as well as the absence of confirmatory tests in many studies.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Immunology
Roberto S. Accolla
Summary: This review discusses the expression of HTLV-1 basic leucine-zipper factor HBZ during HTLV-1 infection, providing a deeper understanding of HTLV-1 infection and oncogenesis mechanisms, and suggesting new directions for further research.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Asami Yamada, Jun-ichirou Yasunaga, Lihan Liang, Wenyi Zhang, Junya Sunagawa, Shinji Nakaoka, Shingo Iwami, Yasunori Kogure, Yuta Ito, Keisuke Kataoka, Masanori Nakagawa, Masako Iwanaga, Atae Utsunomiya, Ki-Ryang Koh, Toshiki Watanabe, Kisato Nosaka, Masao Matsuoka
Summary: This study demonstrates that profiling the humoral immunity to HTLV-1 antigens and measuring proviral load can be used to classify disease status and predict the development of HTLV-1-associated diseases. The study also highlights the importance of anti-Gag proteins in disease prognosis.
Review
Immunology
Jason Cheung, Beata Zahorowska, Michael Suranyi, Jeffrey K. W. Wong, Jason Diep, Stephen T. T. Spicer, Nirupama D. D. Verma, Suzanne J. Hodgkinson, Bruce M. M. Hall
Summary: The immune response to an allograft can activate lymphocytes that cause rejection. The activation of T regulatory cells can reduce allograft rejection and induce immune tolerance. Activated T regulatory cells can be distinguished by various markers. A more detailed characterization of these cells may help reduce non-specific immunosuppression.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Mariele Guerra, Natalia B. Carvalho, Silvane Santos, Mauricio T. T. Nascimento, Renata Sa, Augusto M. M. Carvalho, Edgar M. M. Carvalho, Lucas P. P. Carvalho
Summary: This study found that HTLV-1 infected individuals, especially those with HAM/TSP, have higher levels of MMP-9 production. MMP-9 levels are positively correlated with viral load and TNF levels. These findings suggest an association between MMP-9 production and the proinflammatory state associated with HTLV-1 infection.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Tatiane Assone, Soraya Maria Menezes, Fernanda de Toledo Goncalves, Victor Angelo Folgosi, Gabriela da Silva Prates, Tim Dierckx, Marcos Braz, Jerusa Smid, Michel E. Haziot, Rosa M. N. Marcusso, Flavia E. Dahy, Evelien Vanderlinden, Sandra Claes, Dominique Schols, Roberta Bruhn, Edward L. Murphy, Augusto Cesar Penalva de Oliveira, Dirk Daelemans, Jurgen Vercauteren, Jorge Casseb, Johan Van Weyenbergh
Summary: This study investigated potential biomarkers of immunopathogenesis and therapeutic response in HAM/TSP. The results showed that older age, female sex, and higher proviral load are risk factors for HAM/TSP. Systemic cytokine IL-6 and the chronic inflammatory marker GlycA displayed an "inflammaging" signature in asymptomatic individuals, but not in HAM/TSP patients. IFN-gamma and IL-17A were identified as biomarkers of untreated HAM/TSP, while pre-treatment GlycA and TNF levels predicted therapeutic response to prednisolone pulse therapy.
JOURNAL OF NEUROINFLAMMATION
(2022)
Article
Immunology
Eric A. Meyerowitz, Shibani S. Mukerji, G. Kyle Harrold, Rachel M. Erdil, Steven T. Chen, Emily A. Rudmann, Athe Tsibris, Nagagopal Venna, Gregory K. Robbins
Summary: Mogamulizumab shows potential for improving symptoms in patients with HAM/TSP, but more clinical trials are needed to confirm its effectiveness.
CLINICAL INFECTIOUS DISEASES
(2023)
Review
Oncology
Osamu Yoshie
Summary: CCR4, a chemokine receptor mainly expressed by T cells, has been extensively studied for its selective expression on various T cell subsets and its role as a therapeutic target in cancer immunotherapy. The fully humanized and glyco-engineered monoclonal anti-CCR4 antibody Mogamulizumab has shown remarkable success in the treatment of refractory/relapsed ATLL and CTCLs. However, its efficient depletion of regulatory T cells can lead to severe adverse events, posing challenges in certain treatment settings. Studies on Mogamulizumab's application in advanced solid tumors are ongoing, highlighting its potential in expanding the clinical utility of CCR4 targeting therapies.
Article
Medicine, General & Internal
Nicolle Rakanidis Machado, Beatriz Oliveira Fagundes, Lorena Abreu Fernandes, Augusto Cesar Penalva de Oliveira, Youko Nukui, Jorge Casseb, Fernando Roberto Machado Cunha, Luiz Henrique da Silva Nali, Sabri Saeed Sanabani, Jefferson Russo Victor
Summary: This study found that IgG obtained from HAM/TSP and ATLL patients can differentially modulate the cytokine production by human T and B cells, and elicit distinct effects on target populations.
FRONTIERS IN MEDICINE
(2023)
Review
Medicine, General & Internal
Keiko Tamaki, Hidekazu Mera, Sho Takeshita, Shinsuke Fujioka, Maki Goto, Taichi Matsumoto, Yoshihisa Yamano, Yasushi Takamatsu, Yoshio Tsuboi
Summary: This case is a rare presentation of rapidly progressive HAM/TSP with lymphoma-type ATL, where the patient did not respond to steroids and chemotherapy. Abnormal lymphocytes in the cerebrospinal fluid suggested possible infiltration of ATL cells into the brain and spinal cord.
Article
Microbiology
Daisuke Kodama, Masakazu Tanaka, Toshio Matsuzaki, Satoshi Nozuma, Eiji Matsuura, Hiroshi Takashima, Shuji Izumo, Ryuji Kubota
Summary: The study compared the performance of different detection methods in the CSF of HAM/TSP patients and HTLV-1 carriers, demonstrating that CLIA was closer to PA in performance, while CLEIA had lower sensitivity.
JOURNAL OF CLINICAL MICROBIOLOGY
(2021)
Article
Immunology
Annika P. Schnell, Stephan Kohrt, Aris Aristodemou, Graham P. Taylor, Charles R. M. Bangham, Andrea K. Thoma-Kress
Summary: The pan-HDACi Panobinostat and class I HDACi Romidepsin have been identified as potent agents in enhancing Tax expression in HTLV-1. However, the increase in Tax protein levels is only moderate.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Medicine, General & Internal
Tomoo Sato, Ariella L. G. Coler-Reilly, Naoko Yagishita, Natsumi Araya, Eisuke Inoue, Rie Furuta, Toshiki Watanabe, Kaoru Uchimaru, Masao Matsuoka, Naoki Matsumoto, Yasuhiro Hasegawa, Yoshihisa Yamano
NEW ENGLAND JOURNAL OF MEDICINE
(2018)
Article
Immunology
Madoka Kuramitsu, Kazu Okuma, Makoto Nakashima, Tomoo Sato, Daisuke Sasaki, Hiroo Hasegawa, Kazumi Umeki, Ryuji Kubota, Keiko Sasada, Rieko Sobata, Chieko Matsumoto, Noriaki Kaneko, Kenta Tezuka, Sahoko Matsuoka, Atae Utsunomiya, Ki-Ryang Koh, Masao Ogata, Kenji Ishitsuka, Mai Taki, Kisato Nosaka, Kaoru Uchimaru, Masako Iwanaga, Yasuko Sagara, Yoshihisa Yamano, Akihiko Okayama, Kiyonori Miura, Masahiro Satake, Shigeru Saito, Toshiki Watanabe, Isao Hamaguchi
MICROBIOLOGY AND IMMUNOLOGY
(2018)
Article
Biochemistry & Molecular Biology
Ryoji Fujii, Rie Komatsu, Tomoo Sato, Iwao Seki, Koji Konomi, Hiroyuki Aono, Hisateru Niki, Kazuo Yudoh, Kusuki Nishioka, Toshihiro Nakajima
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2018)
Article
Microbiology
Keiko Tamaki, Tomoo Sato, Jun Tsugawa, Shinsuke Fujioka, Naoko Yagishita, Natsumi Araya, Junji Yamauchi, Ariella L. G. Coler-Reilly, Misako Nagasaka, Yasuhiro Hasegawa, Yoshihisa Yamano, Yoshio Tsuboi
FRONTIERS IN MICROBIOLOGY
(2019)
Letter
Clinical Neurology
Junji Yamauchi, Tomoo Sato, Naoko Yagishita, Natsumi Araya, Daisuke Hasegawa, Shuntaro Tsutsumi, Misako Nagasaka, Ariella Coler-Reilly, Eisuke Inoue, Ayako Takata, Yasuhiro Hasegawa, Yoshihisa Yamano
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
(2020)
Article
Genetics & Heredity
Shuntaro Tsutsumi, Tomoo Sato, Naoko Yagishita, Junji Yamauchi, Natsumi Araya, Daisuke Hasegawa, Misako Nagasaka, Ariella L. G. Coler-Reilly, Eisuke Inoue, Ayako Takata, Yoshihisa Yamano
ORPHANET JOURNAL OF RARE DISEASES
(2019)
Article
Cell Biology
Hiroo Katsuya, Saiful Islam, Benjy Jek Yang Tan, Jumpei Ito, Paola Miyazato, Misaki Matsuo, Yuki Inada, Saori C. Iwase, Yoshikazu Uchiyama, Hiroyuki Hata, Tomoo Sato, Naoko Yagishita, Natsumi Araya, Takaharu Ueno, Kisato Nosaka, Masahito Tokunaga, Makoto Yamagishi, Toshiki Watanabe, Kaoru Uchimaru, Jun-ichi Fujisawa, Atae Utsunomiya, Yoshihisa Yamano, Yorifumi Satou
Article
Multidisciplinary Sciences
Misako Nagasaka, Makoto Yamagishi, Naoko Yagishita, Natsumi Araya, Seiichiro Kobayashi, Junya Makiyama, Miyuki Kubokawa, Junji Yamauchi, Daisuke Hasegawa, Ariella L. G. Coler-Reilly, Shuntaro Tsutsumi, Yu Uemura, Ayako Arai, Ayako Takata, Eisuke Inoue, Yasuhiro Hasegawa, Toshiki Watanabe, Yutaka Suzuki, Kaoru Uchimaru, Tomoo Sato, Yoshihisa Yamano
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2020)
Article
Genetics & Heredity
Natsuko Yamakawa, Naoko Yagishita, Tomohiro Matsuo, Junji Yamauchi, Takahiko Ueno, Eisuke Inoue, Ayako Takata, Misako Nagasaka, Natsumi Araya, Daisuke Hasegawa, Ariella Coler-Reilly, Shuntaro Tsutsumi, Tomoo Sato, Abelardo Araujo, Jorge Casseb, Eduardo Gotuzzo, Steven Jacobson, Fabiola Martin, Marzia Puccioni-Sohler, Graham P. Taylor, Yoshihisa Yamano
ORPHANET JOURNAL OF RARE DISEASES
(2020)
Review
Pharmacology & Pharmacy
Junji Yamauchi, Natsumi Araya, Naoko Yagishita, Tomoo Sato, Yoshihisa Yamano
Summary: HAM/TSP is a rare inflammatory disease that causes unremitting and progressive neurological disorders. Immune-modulating agents are used to slow disease progression, but the lack of surrogate biomarkers hampers clinical trials and the assessment of treatment efficacy. The identification of biomarkers associated with viral components or inflammatory mediators is crucial for improving patient care and developing therapies for HAM/TSP.
PHARMACOLOGY & THERAPEUTICS
(2021)
Article
Virology
Kazu Okuma, Madoka Kuramitsu, Toshihiro Niwa, Tomokuni Taniguchi, Yumiko Masaki, Gohzoh Ueda, Chieko Matsumoto, Rieko Sobata, Yasuko Sagara, Hitomi Nakamura, Masahiro Satake, Kiyonori Miura, Naoki Fuchi, Hideaki Masuzaki, Akihiko Okayama, Kazumi Umeki, Yoshihisa Yamano, Tomoo Sato, Masako Iwanaga, Kaoru Uchimaru, Makoto Nakashima, Atae Utsunomiya, Ryuji Kubota, Kenji Ishitsuka, Hiroo Hasegawa, Daisuke Sasaki, Ki-Ryang Koh, Mai Taki, Kisato Nosaka, Masao Ogata, Isao Naruse, Noriaki Kaneko, Sara Okajima, Kenta Tezuka, Emi Ikebe, Sahoko Matsuoka, Kazuo Itabashi, Shigeru Saito, Toshiki Watanabe, Isao Hamaguchi
Article
Neurosciences
Yoko Tsuchihashi, Takahiro Shimizu, Hisanao Akiyama, Yuta Hagiwara, Kaima Soga, Naoki Takao, Kenji Uchino, Toshiyuki Yanagisawa, Junji Yamauchi, Tomoo Sato, Yasuhiro Hasegawa, Yoshihisa Yamano
JOURNAL OF STROKE & CEREBROVASCULAR DISEASES
(2020)
Article
Multidisciplinary Sciences
Marina Penova, Shuji Kawaguchi, Jun-ichirou Yasunaga, Takahisa Kawaguchi, Tomoo Sato, Meiko Takahashi, Masakazu Shimizu, Mineki Saito, Kunihiro Tsukasaki, Masanori Nakagawa, Norihiro Takenouchi, Hideo Hara, Eiji Matsuura, Satoshi Nozuma, Hiroshi Takashima, Shuji Izumo, Toshiki Watanabe, Kaoru Uchimaru, Masako Iwanaga, Atae Utsunomiya, Yasuharu Tabara, Richard Paul, Yoshihisa Yamano, Masao Matsuoka, Fumihiko Matsuda
Summary: This study identified strong associations in HLA class I and class II loci with HAM/TSP, with specific alleles like HLAC*07:02, HLA-B*07:02, HLA-DRB1*01:01, and HLA-DQB1*05:01 related to disease risk. Conversely, alleles like HLA-B*40:06, HLA-DRB1*15:01, and HLA-DQB1*06:02 were found to be protective. The amino acid residue DRB1-GB-7-Leu was identified as a genetic risk factor for HAM/TSP development independently of proviral load, serving as a specific marker for disease risk.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Kaima Soga, Takahiro Shimizu, Yuta Hagiwara, Hana Ogura, Hisanao Akiyama, Junji Yamauchi, Tomoo Sato, Kazuhiko Hanzawa, Yasuhiro Hasegawa, Yoshihisa Yamano
Summary: In acute stroke patients, SOV dilation, history of stroke, and elevated hematocrit level were found to be associated with the risk of developing a new DVT.
JOURNAL OF MEDICAL ULTRASONICS
(2021)
Meeting Abstract
Clinical Neurology
K. Tamaki, T. Sato, J. Tsugawa, S. Fujioka, N. Yagishita, N. Araya, J. Yamauchi, M. Nagasaka, S. Tsutsumi, Y. Yamano, Y. Tsuboi
JOURNAL OF THE NEUROLOGICAL SCIENCES
(2019)